A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Subjects

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs JNJ 61393215 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 23 Dec 2016 Status changed from recruiting to completed.
    • 14 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
    • 24 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top